Firm acquired by Elan Corporation (NYSE: ELAN) and removed from SBIR Index. Liposome Company Inc researches, developments, manufactures and markets of lipid and liposome-based pharmaceuticals and breast cancer pharmaceuticals. The company selectively develops proprietary parenteral pharmaceuticals for the treatment, prevention and diagnosis of inadequately treated, life-threatening diseases such as severe, systemic fungal infections and inflammatory and vaso-occlusive diseases. Products are sold to hospitals and the home healthcare industry. Manufacturing BranchesThe Liposome Company develops and markets lipid- and liposome-based drugs for treating cancer and other illnesses. The company's primary product, ABELCET, treats various fungal infections in patients with weakened immune systems; Liposome markets the drug directly in North America and the UK, and sells internationally through marketing agreements with other pharmaceutical companies. Utilizing its liposomal technology, the company is also developing treatments for breast, prostate, lung, and other cancers, and is working on a gene-based drug-delivery system.
